Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 772,685
  • Shares Outstanding, K 61,227
  • Annual Sales, $ 6,480 K
  • Annual Income, $ -51,020 K
  • 60-Month Beta 0.46
  • Price/Sales 126.57
  • Price/Cash Flow N/A
  • Price/Book 3.79
Trade ACRS with:

Options Overview Details

View History
  • Implied Volatility 82.03%
  • Historical Volatility 68.74%
  • IV Percentile 9%
  • IV Rank 2.91%
  • IV High 417.93% on 12/07/20
  • IV Low 71.97% on 06/25/21
  • Put/Call Vol Ratio 0.48
  • Today's Volume 31
  • Volume Avg (30-Day) 112
  • Put/Call OI Ratio 3.10
  • Today's Open Interest 119
  • Open Int (30-Day) 1,033

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.36
  • Number of Estimates 5
  • High Estimate -0.34
  • Low Estimate -0.39
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -16.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.33 +2.35%
on 11/23/21
18.62 -32.23%
on 11/01/21
-3.34 (-20.93%)
since 10/26/21
3-Month
12.33 +2.35%
on 11/23/21
19.97 -36.81%
on 09/27/21
-1.67 (-11.69%)
since 08/26/21
52-Week
3.20 +294.38%
on 11/30/20
30.38 -58.45%
on 04/08/21
+9.31 (+281.27%)
since 11/25/20

Most Recent Stories

More News
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

Investigational New Drug Application for ATI-2138 Allowed WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a...

ACRS : 12.62 (-5.82%)
Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...

ACRS : 12.62 (-5.82%)
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 12.62 (-5.82%)
Aclaris: Q3 Earnings Snapshot

WAYNE, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Tuesday reported a loss of $21.1 million in its third quarter.

ACRS : 12.62 (-5.82%)
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021Planning to Initiate Phase 2b Trial of...

ACRS : 12.62 (-5.82%)
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRS : 12.62 (-5.82%)
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aclaris Therapeutics, Inc. – ACRS

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed...

ACRS : 12.62 (-5.82%)
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

ACRS : 12.62 (-5.82%)
Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

ACRS : 12.62 (-5.82%)
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...

ACRS : 12.62 (-5.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 13.95
2nd Resistance Point 13.59
1st Resistance Point 13.11
Last Price 12.62
1st Support Level 12.27
2nd Support Level 11.91
3rd Support Level 11.43

See More

52-Week High 30.38
Fibonacci 61.8% 19.99
Fibonacci 50% 16.79
Fibonacci 38.2% 13.58
Last Price 12.62
52-Week Low 3.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar